A detailed history of Lazard Asset Management LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 102,012 shares of NTLA stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,012
Previous 116,390 12.35%
Holding current value
$1.55 Million
Previous $2.6 Million 19.51%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $283,534 - $393,382
-14,378 Reduced 12.35%
102,012 $2.1 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $527,166 - $716,757
26,332 Added 29.24%
116,390 $2.6 Million
Q1 2024

May 14, 2024

SELL
$23.82 - $32.8 $290,008 - $399,339
-12,175 Reduced 11.91%
90,058 $2.48 Million
Q4 2023

Feb 14, 2024

SELL
$23.16 - $32.34 $90,717 - $126,675
-3,917 Reduced 3.69%
102,233 $3.12 Million
Q3 2023

Nov 14, 2023

SELL
$31.62 - $45.78 $42,022 - $60,841
-1,329 Reduced 1.24%
106,150 $3.36 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $35,306 - $46,996
1,021 Added 0.96%
107,479 $4.38 Million
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $1.96 Million - $2.64 Million
58,951 Added 124.09%
106,458 $3.97 Million
Q4 2022

Feb 14, 2023

SELL
$33.21 - $62.69 $1.32 Million - $2.5 Million
-39,889 Reduced 45.64%
47,507 $1.66 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $268,036 - $356,420
4,971 Added 6.03%
87,396 $4.89 Million
Q2 2022

Aug 09, 2022

BUY
$38.49 - $76.21 $3.15 Million - $6.24 Million
81,876 Added 14913.66%
82,425 $4.27 Million
Q1 2022

May 13, 2022

BUY
$58.27 - $118.99 $8,507 - $17,372
146 Added 36.23%
549 $39,000
Q4 2021

Feb 09, 2022

BUY
$100.76 - $138.36 $39,598 - $54,375
393 Added 3930.0%
403 $47,000
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $1,323 - $1,767
10 New
10 $1,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.16B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.